In a significant setback, Tango Therapeutics has announced that it is stopping the development of its cancer therapy after observing liver toxicity in patients participating in a phase 1 clinical trial. The company's USP1 inhibitor, which was being tested as a potential treatment for various types of cancer, has been suspended due to the adverse reaction.
The decision to halt the trial was made after an independent data monitoring committee (IDMC) reviewed the data and recommended stopping the study due to the risk of liver toxicity. This decision was also supported by the US Food and Drug Administration (FDA).
Tango Therapeutics is not the only company to face setbacks in its cancer therapy development. In recent years, several pharmaceutical companies have encountered similar issues, leading to the abandonment of promising treatments.
The company's decision to stop the development of its USP1 inhibitor is a significant blow to its pipeline and its investors. However, Tango Therapeutics has stated that it will continue to explore other potential treatments and will not be deterred by this setback.
The company's decision to stop the development of its USP1 inhibitor is a reminder of the challenges and risks involved in developing new cancer therapies. Despite the setbacks, researchers and pharmaceutical companies continue to work towards finding effective treatments for this devastating disease.
**Sources:**
* Fierce Biotech: Tango drops USP1 inhibitor over liver toxicity in phase 1 trial
* BioSpace: Tango Stops Early Cancer Trial Over Liver Toxicity, Drops Out of Race Against Roche
* XM: Tango Therapeutics falls after stopping cancer therapy
* Investing.com UK: Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
* SaltWire Halifax powered by The Chronicle Herald: Tango Therapeutics to stop development of cancer therapy
